Celtik, A.Alpay, N.Celik, A.Sezer, T. O.Turkmen, A.Camsari, T.Toz, H.Sever, M. S.Hoscoskun, C.2019-10-272019-10-2720130041-1345https://doi.org/10.1016/j.transproceed.2013.02.051https://hdl.handle.net/11454/476479th Congress of the Turkish-Transplantation-Centers-Coordination-Association (TTCCA) -- SEP 26-29, 2012 -- Bursa, TURKEYBackground. Renal transplantation is the best renal replacement therapy because it significantly improves patient survival. The developments in transplantation and increasing number of patients with end-stage renal disease (ESRD) have unmasked long-term complications secondary to immunosuppressive drugs and chronic renal failure. Methods and Results. Eighty-six renal transplant recipients with grafts that have functioned more than 15 years were included in the study. This cross-sectional retrospective analysis of demographic, clinical, and laboratory findings was conducted in 3 Turkish transplantation centers. The mean age was 30.4 +/- 10.2 years at the time of the transplantation. The mean time between the transplantation and the study was 19.1 +/- 3.6 years. At the time of the study, mean creatinine level was 1.52 +/- 0.60 mg/dL, 70.09% of the patients displayed glomerular filtration rates <60 mL/min/1.73 m(2). Urinary protein excretion was 0.57 +/- 0.65 g/d. Hypertension and hyperlipidemia were the most common comorbid diseases. Twelve patients had diabetes and 9 cardiovascular disease. Seventeen patients had been diagnosed with skin and 5 with non-skin cancer. Conclusions. As the number of recipients with long-term functioning grafts increases, long-term complications become evident, particularly chronic renal failure. Survivors should be evaluated regularly and treated early for risk factors and complications to improve long-term graft and patient survival.en10.1016/j.transproceed.2013.02.051info:eu-repo/semantics/closedAccessArticle453904907WOS:00031845700001523622583Q3Q3